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Sir,
Vulval intraepithelial neoplasia (VIN) is resulted from persistent
human papillomavirus (HPV) infection, especially infection of
HPV type 16 (HPV16) (Trimble and Frazer, 2009). Several studies
have shown the effectiveness of topical administration of
Imiquimod, a Toll-like receptor 7 agonist, for the treatment of
VIN (Davis et al, 2000; Diaz-Arrastia et al, 2001). Recently, these
results are confirmed by a randomized, placebo-controlled clinical
study (van Seters et al, 2008). The HPV16-related Th1 responses,
especially local Th1 responses, are critical for the favoured clinical
outcome after Imiquimod treatment (van Poelgeest et al, 2005;
van Seters et al, 2008).
Daayana et al (2010) further showed in a paper published in
British Journal of Cancer that Imiquimod topical application
followed by HPV therapeutic vaccine led to the complete
regression of VIN in 63% of patients recruited in a Phase II
clinical trial at 52 weeks after the treatment. There was significantly
increased local infiltration of CD8 and CD4 T cells in responders;
whereas non-responders showed an increased density of
T regulatory cells in the lesions (Daayana et al, 2010). The authors
speculated that genetic predisposition involving immune and other
parameters may be responsible for the differences between
responders and non-responders. Similar clinical outcome was
observed in VIN patients treated with Imiquimod topical
application followed by photodynamic therapy from the same
group (Winters et al, 2008), although the underlying mechanisms
of therapeutic vaccination and photodynamic treatment after
Imiquimod application may be different. Interestingly, the
non-responders also showed a significantly higher level of
T regulatory cells in the lesions after Imiquimod treatment
(Winters et al, 2008).
Activation of TLRs not only induces inflammatory cytokines,
such as TNFa and IFNg, but also promotes the secretion of IL10, an
inhibitory cytokine that damps immune responses (Saraiva and
O’Garra, 2010). Topical application of Imiquimod to a transgenic
mice bearing HER-2/neuþ breast cancer induces high level of
IL10 (Lu et al, 2010), which promotes tumour progress after the
treatment is ended. The IL10 is secreted by a population of
CD4þ T cells also secreting IFNg, and these cells are most likely
responsible for the ineffectiveness of Imiquimod therapy. The IL10
secreting T regulatory cells can be amplified by the subsequent
vaccination (Zhou et al, 2006). Blocking IL10 increases cytotoxic
T cells responses activated through TLRs and enhances the
antitumour effect of Imiquimod by significantly prolonging
survival in treated mice (Liu et al, 2006; Lu et al, 2010).
IL10 polymorphism influences IL12 secretion by dendritic cells
in response to the TLRs stimulation (Peng et al, 2006), thus control
the level of Th1 responses, which is critical for control tumour
growth. It is likely that in non-responder patients, the CD4þ
T cells secrete more IL10 in response to Imiquimod application,
prevent the generation of CD4 and CD8 effector T cells that are
able to migrate to the tumour site to kill tumour cells. It is worth
investigating the level of IL10, and IL10 polymorphism after
Imiquimod application in responders and non-responders;
and whether blocking IL10 signalling at the time of Imiquimod
application further improves the efficacy of the treatment.
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